TY - JOUR
T1 - Functional roles of the interaction of APP and lipoprotein receptors
AU - Pohlkamp, Theresa
AU - Wasser, Catherine R.
AU - Herz, Joachim
N1 - Funding Information:
This work was supported by grants from the NHLBI (R37 HL063762), the NIA (RF AG053391), the NINDS and NIA (RO1 NS093382), as well as, the Consortium for Frontotemporal Dementia Research (A108400), and the Brightfocus Foundation (A2016396S). We would like to thank Nancy Heard and Barbara Dacus for their help in preparing the figures.
Publisher Copyright:
© 2017 Pohlkamp, Wasser and Herz.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - The biological fates of the key initiator of Alzheimer’s disease (AD), the amyloid precursor protein (APP), and a family of lipoprotein receptors, the low-density lipoprotein (LDL) receptor-related proteins (LRPs) and their molecular roles in the neurodegenerative disease process are inseparably interwoven. Not only does APP bind tightly to the extracellular domains (ECDs) of several members of the LRP group, their intracellular portions are also connected through scaffolds like the one established by FE65 proteins and through interactions with adaptor proteins such as X11/Mint and Dab1. Moreover, the ECDs of APP and LRPs share common ligands, most notably Reelin, a regulator of neuronal migration during embryonic development and modulator of synaptic transmission in the adult brain, and Agrin, another signaling protein which is essential for the formation and maintenance of the neuromuscular junction (NMJ) and which likely also has critical, though at this time less well defined, roles for the regulation of central synapses. Furthermore, the major independent risk factors for AD, Apolipoprotein (Apo) E and ApoJ/Clusterin, are lipoprotein ligands for LRPs. Receptors and ligands mutually influence their intracellular trafficking and thereby the functions and abilities of neurons and the blood-brain-barrier to turn over and remove the pathological product of APP, the amyloid-b peptide. This article will review and summarize the molecular mechanisms that are shared by APP and LRPs and discuss their relative contributions to AD.
AB - The biological fates of the key initiator of Alzheimer’s disease (AD), the amyloid precursor protein (APP), and a family of lipoprotein receptors, the low-density lipoprotein (LDL) receptor-related proteins (LRPs) and their molecular roles in the neurodegenerative disease process are inseparably interwoven. Not only does APP bind tightly to the extracellular domains (ECDs) of several members of the LRP group, their intracellular portions are also connected through scaffolds like the one established by FE65 proteins and through interactions with adaptor proteins such as X11/Mint and Dab1. Moreover, the ECDs of APP and LRPs share common ligands, most notably Reelin, a regulator of neuronal migration during embryonic development and modulator of synaptic transmission in the adult brain, and Agrin, another signaling protein which is essential for the formation and maintenance of the neuromuscular junction (NMJ) and which likely also has critical, though at this time less well defined, roles for the regulation of central synapses. Furthermore, the major independent risk factors for AD, Apolipoprotein (Apo) E and ApoJ/Clusterin, are lipoprotein ligands for LRPs. Receptors and ligands mutually influence their intracellular trafficking and thereby the functions and abilities of neurons and the blood-brain-barrier to turn over and remove the pathological product of APP, the amyloid-b peptide. This article will review and summarize the molecular mechanisms that are shared by APP and LRPs and discuss their relative contributions to AD.
KW - APOE
KW - Amyloid beta
KW - Glutamate receptors
KW - LDL receptor gene family
KW - LRP
KW - Neuromuscular junction
KW - Synapse
KW - Trafficking
UR - http://www.scopus.com/inward/record.url?scp=85019222907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019222907&partnerID=8YFLogxK
U2 - 10.3389/fnmol.2017.00054
DO - 10.3389/fnmol.2017.00054
M3 - Review article
C2 - 28298885
AN - SCOPUS:85019222907
SN - 1662-5099
VL - 10
JO - Frontiers in Molecular Neuroscience
JF - Frontiers in Molecular Neuroscience
M1 - 54
ER -